| PAD+/MetS+ (n = 57) | PAD+/MetS- (n = 157) | PAD-/MetS+ (n = 55) | PAD-/MetS- (n = 142) | p-value |
---|---|---|---|---|---|
Aspirin (%) | 67.9 | 67.8 | 58.2 | 52.8 | 0.006 |
Clopidogrel (%) | 26.8 | 31.1 | 3.6 | 4.9 | <0.001 |
Metformin (%) * | 30.3 | 5.1 | 9.1 | 5.6 | 0.007 |
Sulfonyrea (%) * | 24.2 | 3.4 | 3.6 | 5.6 | 0.050 |
Glitazone (%) * | 6.1 | 0.9 | 0.0 | 0.0 | 0.011 |
Insulin (%) * | 15.2 | 10.3 | 3.6 | 5.6 | 0.040 |
Statins (%) | 75.0 | 69.2 | 21.8 | 28.2 | 0.003 |
Angiotensin Converting Enzyme Inhibitors (%) | 49.1 | 40.1 | 24.5 | 23.9 | <0.001 |
Calcium Antagonists (%) | 36.8 | 29.3 | 10.9 | 8.5 | <0.001 |
Beta Adrenoreceptor Blocking Agents (%) | 31.6 | 40.1 | 61.8 | 38.0 | 0.459 |
Angiotensin II Receptor Blocking Agents (%) | 12.3 | 10.8 | 9.1 | 4.9 | 0.042 |